Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RETSEVMO CAPSULES 40MG - PPB Drug Approval Details

Approvals/PPB/RETSEVMO CAPSULES 40MG

Approved

STANDARD

RETSEVMO CAPSULES 40MG

ELI LILLY ASIA, INC.🇰🇪 Pharmacy and Poisons Board

Approval Date: Jun 21, 2024
Approval ID: 33ff326f6ab0bc04
Company: ELI LILLY ASIA, INC.
Type: Standard

Approval Details

Approval Id: 33ff326f6ab0bc04
Product Name: RETSEVMO CAPSULES 40MG
Drug Hk Name: RETSEVMO CAPSULES 40MG
Registration Code: HK-67999
Company Name: ELI LILLY ASIA, INC.
Company Detail Path: /organization/e25e410e7e280895/eli-lilly-asia-inc
Registration Category: Part 1, Schedule 1 & Schedule 3 Poison
Sale Requirement: Prescription only Medicines
Registration Date: 2023-10-30
Company Address: RM 3203-06 32/F, CHUBB TOWER WINDSOR HOUSE, 311 GLOUCESTER ROAD, CAUSEWAY BAY, HONG KONG

Active Ingredients

Approved

Quick Info

Agency

PPB

Country

🇰🇪

Approval Date

Jun 21, 2024

Approval ID

33ff326f6ab0bc04

Type

Standard

Back to PPB Approvals